Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Operations (2021 - 2025)

Prime Medicine (PRME) has disclosed Cash from Operations for 5 consecutive years, with 37256000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 329.34% year-over-year to 37256000.0, compared with a TTM value of 162564000.0 through Dec 2025, down 32.31%, and an annual FY2025 reading of 162564000.0, down 32.31% over the prior year.
  • Cash from Operations was 37256000.0 for Q4 2025 at Prime Medicine, down from 35039000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 16245000.0 in Q4 2024 and bottomed at 67707000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 35050294.12, with a median of 39166000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations soared 137.03% in 2024, then tumbled 329.34% in 2025.
  • Year by year, Cash from Operations stood at 13187000.0 in 2021, then crashed by 132.9% to 30713000.0 in 2022, then crashed by 42.82% to 43864000.0 in 2023, then skyrocketed by 137.03% to 16245000.0 in 2024, then plummeted by 329.34% to 37256000.0 in 2025.
  • Business Quant data shows Cash from Operations for PRME at 37256000.0 in Q4 2025, 35039000.0 in Q3 2025, and 41412000.0 in Q2 2025.